Role of Cytochrome P450 Enzymes in Drug-Drug Interactions

Advances in Pharmacology

Volumn 43, Issue C, 1997, Pages 7-35

  Guengerich, F Peter ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYP3A PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 2D6; DRUG; ETHINYLESTRADIOL; MIXED FUNCTION OXIDASE; TERFENADINE;

ANIMAL; BEVERAGE; BINDING SITE; CITRUS FRUIT; DRUG ANTAGONISM; DRUG INTERACTION; FOOD DRUG INTERACTION; HUMAN; METABOLISM; REVIEW;

ANIMALS; BEVERAGES; BINDING SITES; CIMETIDINE; CITRUS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FOOD-DRUG INTERACTIONS; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACEUTICAL PREPARATIONS; TERFENADINE;

EID: 0030627336     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60200-8     Document Type: Article

References (163)

1. Andersson T., Regårdh C.G., Dahl-Puustinen M.L., and Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Thera. Drug Monit. 12 (1990) 415-416
2. Andersson T., Miners J.O., Veronese M.E., Tassaneeyakul W., Meyer U.A., and Birkett D.J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36 (1993) 521-530
3. Aoyama T., Yamano S., Waxman D.J., Lapenson D.P., Meyer U.A., Fischer V., Tyndale R., Inaba T., Kalow W., Gelboin H.V., and Gonzalez F.J. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 264 (1989) 10388-10395
4. Bailey D.G. Food-drug interactions: Emphasis on grapefruit juice effects. Can. J. Clin. Pharmacol. 2 (1995) 10-14
5. Bailey D.G., Spence J.D., Munoz C., and Arnold J.M.O. Interaction of citrus juices with felodipine and nifedipine. Lancet 337 (1991) 268-269
6. Bailey D.G., Arnold J.M.O., Strong H.A., Munoz C., and Spence J.D. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin. Pharmacol. Ther. 54 (1993) 589-594
7. Bailey D.G., Arnold J.M.O., and Spence J.D. Grapefruit juice and drugs: how significant is the interaction. Clin Pharmacokinet. 26 (1994) 91-98
8. Bars R.G., Bell D.R., and Elcombe C.R. Induction of cytochrome P450 and peroxisomal enzymes by clofibric acid in vivo and in vitro. Biochem. Pharmacol. 45 (1993) 2045-2053
9. Beaune P., Dansette P., Flinois J.P., Columelli S., Mansuy D., and Leroux J.P. Partial purification of human liver cytochrome P-450. Biochem. Biophys. Res. Commun. 88 (1979) 826-832
10. Bell D.R., Plant N.J., Rider C.C., Na L., Brown S., Ateitalla I., Acharya S.K., Davies M.H., Elias E., Jenkins N.A., Gilbert D.J., Copeland N.G., and Elcombe C.R. Species-specific induction of cytochrome P-450 4A RNAs: PCR cloning of partial guinea-pig, human and mouse CYP4A cDNAs. Biochem. J. 294 (1993) 173-180
11. Bensoussan C., Delaforge M., and Mansuy D. Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of amino drugs. Biochem. Pharmacol. 49 (1995) 591-602
12. Böcker R.H., and Guengerich F.P. Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. J. Med. Chem. 29 (1986) 1596-1603
13. Bolt H.M., Kappus H., and Remmer H. Studies on the metabolism of ethynylestradiol in vitro and in vivo: The significance of 2-hydroxylation and the formation of polar products. Xenobiotica 3 (1973) 773-785
14. Bolt H.M., Bolt M., and Kappus H. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol. (Copenhagen) 85 (1977) 189-197
15. Brady J.F., Xiao F., Wang M.H., Li Y., Ning S.M., Gapac J.M., and Yang C.S. Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes, and hepatotoxicity in rats. Toxicol. Appl. Pharmacol. 108 (1991) 366-373
16. Breimer D.D., Zilly W., and Richter E. Influence of corticosteroids on hexobarbital and tolbutamide disposition. Clin. Pharmacol. Ther. 24 (1978) 208-212
17. Brian W.R., Sari M.-A., Iwasaki M., Shimada T., Kaminsky L.S., and Guengerich F.P. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29 (1990) 11280-11292
18. Brodie A.M.H. Aromatase inhibitors in the treatment of breast cancer. J. Steroid Biochem. Mol. Biol. 49 (1994) 281-287
19. Brodie Gillette B.B.J.R., and LaDu B.N. Enzymatic metabolism of drugs and other foreign compounds. Annu. Rev. Biochem. 27 (1958) 427-454
20. Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., and Meyer U.A. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 10 (1991) 545-558
21. Burke M.D. Cytochrome P-450: A pharmacological necessity or a biochemical curiosity. Biochem. Pharmacol. 30 (1981) 181-187
22. Butler M.A., Iwasaki M., Guengerich F.P., and Kadlubar F.F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 7696-7700
23. Butler M.A., Lang N.P., Young J.F., Caporaso N.E., Vineis P., Hayes R.B., Teitel C.H., Massengill J.P., Lawsen M.F., and Kadlubar F.F. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2 (1992) 116-127
24. Cholerton S., Idle M.E., Vas A., Gonzalez F.J., and Idle J.R. Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine. J. Chromatogr. 575 (1992) 325-330
25. Coleman M.D., Tingle M.D., and Park B.K. Inhibition of dapsone-induced methaemoglobinaemia by cimetidine in the rat during chronic dapsone administration. J. Pharm. Pharmacol. 43 (1991) 186-190
26. Combalbert J., Fabre I., Fabre G., Dalet I., Derancourt J., Cano J.P., and Maurel P. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicininducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab. Dispos. 17 (1989) 197-207
27. Conney A.H. Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19 (1967) 317-366
28. Conney A.H., Miller E.C., and Miller J.A. The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res. 16 (1956) 450-459
29. Cupp-Vickery J.R., and Poulos T.L. Structure of cytochrome P450eryF involved in erythromycin biosynthesis. Nature Struct. Biol. 2 (1995) 144-153
30. de Morais S.M.F., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., and Goldstein J.A. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269 (1994) 15419-15422
31. Denison M.S., and Whitlock J.P. Xenobiotic-inducible transcription of cytochrome P450 genes. J. Biol. Chem. 270 (1995) 18175-18178
32. Diaz D., Fabre I., Daujat M., Saintaubert B., Bories P., Michel H., and Maurel P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome-P450. Gastroenterology 99 (1990) 737-747
33. Distlerath L.M., and Guengerich F.P. Enzymology of human liver cytochromes P-450. In: Guengerich F.P. (Ed). "Mammalian Cytochromes P-450" 1 (1987), CRC Press, Boca Raton, FL 133-198
34. Diwan B.A., Rice J.M., Nims R.W., Lubet R.A., Hu H., and Ward J.M. P-450 enzyme induction by 5-ethyl-5-phenylhydantoin and 5,5-diethylhydantoin, analogues of barbiturate tumor promoters phenobarbital and barbital, and promotion of liver and thyroid carcinogenesis initiated by N-nitrosodiethylamine in rats. Cancer Res. 48 (1988) 2492-2497
35. Eichelbaum M., Spannbrucker N., Steincke B., and Dengler H.J. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 16 (1979) 183-187
36. Ellis S.W., Hayhurst G.P., Smith G., Lightfoot T., Wong M.M.S., Simula A.P., Ackland M.J., Sternberg M.J.E., Lennard M.S., Tucker G.T., and Wolf C.R. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J. Biol. Chem. 270 (1995) 29055-29058
37. Evans W.E., Relling M.V., Petros W.P., Meyer W.H., Mirro Jr. J., and Crom W.R. Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin. Pharmacol. Ther. 45 (1989) 568-573
38. Fischbach T., and Lenk W. Additional routes in the metabolism of phenacetin. Xenobiotica 15 (1985) 149-164
39. Fonne-Pfister R., and Meyer U.A. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. Biochem. Pharmacol. 37 (1988) 3829-3835
40. Gan L.S.L., Acebo A.L., and Alworth W.L. 1-Ethynylpyrene, a suicide inhibitor of cytochrome P-450 dependent benzo[a]pyrene hydroxylase activity in liver microsomes. Biochemistry 23 (1984) 3827-3836
41. Ged C., Rouillon J.M., Pichard L., Combalbert J., Bressot N., Bories P., Michel H., Beaune P., and Maurel P. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol. 28 (1989) 373-387
42. Gerber M.C., Tejwani G.A., Gerber N., and Bianchine J.R. Drug interactions with cimetidine: An update. Pharmacol. Ther. 27 (1985) 353-370
43. Gibson G.G. Peroxisome proliferators: Paradigms and prospects. Toxicol. Lett. 68 (1993) 193-201
44. Gillam E.M., Guo Z.J., Ueng Y.-F., Yamazaki H., Cock I., Reilly P.E.B., Hooper W.D., and Guengerich F.P. Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modifications, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys. 317 (1995) 374-384
45. Godin J.R.P., Sketris I.S., and Belitsky P. Erythromycin-cyclosporine interaction. Drug Intell. Clin. Pharm. 20 (1986) 504-505
46. Gonzalez F.J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 40 (1989) 243-288
47. Gonzalez F.J., and Meyer U.A. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin. Pharmacol. Ther. 50 (1991) 233-238
48. Gonzalez F.J., Skoda R.C., Kimura S., Umeno M., Zanger Nebert U.M., Gelboin D.W.H.V., Hardwick J.P., and Meyer U.A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (London) 331 (1988) 442-446
49. Gonzalez F.J., Aoyama T., and Gelboin H.V. Expression of mammalian cytochrome P450 using vaccinia virus. In: Waterman M.R., and Johnson E.F. (Eds). "Methods in Enzymology" 206 (1991), Academic Press, San Diego, CA 85-92
50. Gonzalez F.J., Kimura S., Tamura S., and Gelboin H.V. Expression of mammalian cytochrome P450 using baculovirus. In: Waterman M.R., and Johnson E.F. (Eds). "Methods in Enzymology" 206 (1991), Academic Press, San Diego, CA 93-99
51. Grace J.M., Kinter M.T., and Macdonald T.L. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 7 (1994) 286-290
52. Guengerich F.P. Enzymology of rat liver cytochromes P-450. In: Guengerich F.P. (Ed). "Mammalian Cytochromes P-450" 1 (1987), CRC Press, Boca Raton, FL 1-54
53. Guengerich F.P. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol. Pharmacol. 33 (1988) 500-508
54. Guengerich F.P. Characterization of human microsomal cytochrome P-450 enzymes. Annu. Rev. Pharmacol. Toxicol. 29 (1989) 241-264
55. Guengerich F.P. Mechanism-based inactivation of human liver cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3 (1990) 363-371
56. Guengerich F.P. Metabolism of 17α-ethynylestradiol in humans. Life Sci. 47 (1990) 1981-1988
57. Guengerich F.P. Cytochrome P450 enzymes. Am. Sci. 81 (1993) 440-447
58. Guengerich F.P. Human cytochrome P450 enzymes. In: Ortiz de Montellano P.R. (Ed). "Cytochrome P450". 2nd ed. (1995), Plenum, New York 473-535
59. Guengerich F.P., and Kim D.-H. In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis (London) 11 (1990) 2275-2279
60. Guengerich F.P., and Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4 (1991) 391-407
61. Guengerich F.P., Martin M.V., Beaune P.H., Kremers P., Wolff T., and Waxman D.J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261 (1986) 5051-5060
62. Guengerich F.P., Müller-Enoch D., and Blair I.A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol. 30 (1986) 287-295
63. Guengerich F.P., Kim D.-H., and Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol. 4 (1991) 168-179
64. Guengerich F.P., Gillam E.M.J., Martin M.V., Baba T., Kim B.-R., Shimada T., Raney K.D., and Yun C.-H. The importance of cytochrome P450 3A enzymes in drug metabolism. In: Waterman M.R., and Hildebrand M. (Eds). "Schering Foundation Workshop 13, Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research" (1994), Springer-Verlag, Berlin 161-186
65. Guengerich F.P., Kim B.-R., Gillam E.M.J., and Shimada T. In: Lechner M.C. (Ed). Mechanisms of enhancement and inhibition of cytochrome P450 catalytic activity (1994), John Libbey Eurotext, Paris 97-101 Proceedings of the Eighth International Conference on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology"
66. Guengerich F.P., Gillam E.M.J., and Shimada T. New applications of bacterial systems to problems in toxicology. Crit. Rev. Toxicol. 26 (1996) 551-583
67. Guillouzo A., Morel F., Fardel O., and Meunier B. Use of human hepatocyte cultures for drug metabolism studies. Toxicology 82 (1993) 209-219
68. Guo Z., Gillam E.M.J., Ohmori S., Tukey R.H., and Guengerich F.P. Expression of modified human cytochrome P450 1A1 in Escherichia coli: Effects of 5′ substitution, stabilization, purification, spectral characterization, and catalytic properties. Arch. Biochem. Biophys. 312 (1994) 436-446
69. Halpert J.A., and Guengerich F.P. Enzyme inhibition and stimulation. In: Guengerich F.P. (Ed). "Biotransformation" 3 (1997), Pergamon, New York 21-35
70. Halpert J.A., Miller N.E., and Gorsky L.D. On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J. Biol. Chem. 260 (1985) 8397-8403
71. Hankinson O. Research on the aryl hydrocarbon (dioxin) receptor is primed to take off. Arch. Biochem. Biophys. 300 (1993) 1-5
72. Huang M.T., Johnson E.F., Müller-Eberhard U., Koop D.R., Coon M.J., and Conney A.H. Specificity in the activation and inhibition by flavonoids of benzol[a]pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes. J. Biol. Chem. 256 (1981) 10897-10901
73. Ioannides C., and Parke D.V. The cytochromes P-488-a unique family of enzymes involved in chemical toxicity and carcinogenesis. Biochem. Pharmacol. 36 (1987) 4197-4207
74. Ioannides C., and Parke D.V. The cytochrome P450 I gene family of microsomal hemoproteins and their role in the metabolic activation of chemicals. Drug Metab. Rev. 22 (1990) 1-85
75. Ioannides C., and Parke D.V. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metab. Rev. 25 (1993) 485-501
76. Islam S.A., Wolf C.R., Lennard M.S., and Sternberg M.J.E. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis (London) 12 (1991) 2211-2219
77. Janz D., and Schmidt D. Anti-epileptic drugs and failure of oral contraceptives. Lancet 1 (1974) 1113
78. Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjöqvist F., and Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 11825-11829
79. Jönsson K.H., and Lindeke B. Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines. XII. Enantioselectivity and temperature dependence in microsomes and reconstituted cytochrome P-450 systems from rat liver. Chirality 4 (1992) 469-477
80. Jung-Hoffmann C., and Kuhl H. Interaction with the pharmacokinetics of ethinylestradiol of progestogens contained in oral contraceptives. Contraception 40 (1990) 299-312
81. Kalow W., and Tang B.K. The use of caffeine for enzyme assays: A critical appraisal. Clin. Pharmacol. Ther. 53 (1993) 503-514
82. Kapitulnik J., and Gonzalez F.J. Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat. Mol. Pharmacol. 43 (1993) 722-725
83. Kapitulnik J., and Ostrow J.D. Stimulation of bilirubin catabolism in jaundiced Gunn rats by an inducer of microsomal mixed-function monooxygenases. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 682-685
84. Kerr B.M., Thummel K.E., Wurden C.J., Klein S.M., Kroetz D.L., Gonzalez F.J., and Levy R.H. Human liver carbamazepine metabolism: Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem. Pharmacol. 47 (1994) 1969-1979
85. Kim R.B., O'Shea D., and Wilkinson G.R. Relationship in healthy subjects between CYP2E1 genetic polymorphism and the 6-hydroxylation of chlorzoxazone: A putative measure of CYP2E1 activity. Pharmacogenetics 4 (1994) 162-165
86. Kim R.B., O'Shea D., and Wilkinson G.R. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther. 57 (1995) 645-655
87. Kinirons M.T., O'Shea D., Downing T.E., Fitzwilliam A.T., Joellenbeck L., Groopman J.D., Wilkinson G.R., and Wood A.J.J. Absence of correlations among 3 putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin. Pharmacol. Ther. 54 (1993) 621-629
88. Kitada M., and Kamataki T. Partial purification and properties of cytochrome P450 from homogenates of human fetal livers. Biochem. Pharmacol. 28 (1979) 793-797
89. Kivistö K.T., Neuvonen P.J., and Klotz U. Inhibition of terfenadine metabolism: Pharmacokinetic and pharmacodynamic consequences. Clin. Pharmacokinet. 27 (1994) 1-5
90. Klehr H., Eyer P., and Schäfer W. Formation of 4-ethoxy-4′-nitrosodiphenylamine in the reaction of the phenacetin metabolite 4-nitrosophenetol with glutathione. Biol. Chem. Hoppe-Seyler 368 (1987) 895-902
91. Knodell R.G., Hall S.D., Wilkinson G.R., and Guengerich F.P. Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J. Pharmacol. Exp. Ther. 241 (1987) 1112-1119
92. Knodell R.G., Browne D., Gwodz G.P., Brian W.R., and Guengerich F.P. Differential inhibition of human liver cytochromes P-450 by cimetidine. Gastroenterology 101 (1991) 1680-1691
93. Kolars J.C., Awni W.M., Merion R.M., and Watkins P.B. First-pass metabolism of cyclosporin by the gut. Lancet 338 (1991) 1488-1490
94. Koymans L., Vermeulen N.P.E., te van Acker S.A., Koppele B.E.J.M., Heykants J.J.P., Lavrijsen K., Meuldermans W., and Donne-Op den Kelder G.M. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem. Res. Toxicol. 5 (1992) 211-219
95. Kronbach T., Fischer V., and Meyer U.A. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43 (1988) 630-635
96. Kuby S.A. "A Study of Enzymes," 1 (1991), CRC Press, Boca Raton, FL 253-281
97. Kunze K.L., and Trager W.F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol. 6 (1993) 649-656
98. Lang N.P., Butler M.A., Massengill J., Lawson M., Stotts R.C., Maurer-Jensen M., and Kadlubar F.F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomarkers Prev. 3 (1994) 675-682
99. Lasker J.M., Huang M.-T., and Conney A.H. In vivo activation of zoxazolamine metabolism by flavone. Science 216 (1982) 1419-1421
100. Lee C.A., Thummel K.E., Kalhorn T.F., Nelson S.D., and Slattery J.T. Activation of acetaminophen-reactive metabolite formation by methylxanthines and known cytochrome P-450 activators. Drug Metab. Dispos. 19 (1991) 966-971
101. Lee M.S., Kliewer S.A., Provencal J., Wright P.E., and Evans R.M. Structure of the retinoid X receptor a DNA binding domain: A helix required for homodimeric DNA binding. Science 260 (1993) 1117-1121
102. Lesca P., Peryt B., Larrieu G., Alvinerie M., Galtier P., Daujat M., Maurel P., and Hoogenboom L. Evidence for the ligand-independent activation of the AH receptor. Biochem. Biophys. Res. Commun. 209 (1995) 474-482
103. Levin W., Jacobson M., Sernatinger E., and Kuntzman R. Breakdown of cytochrome P-450 heme by secobarbital and other allyl-containing barbiturates. Drug Metab. Dispos. 1 (1973) 275-285
104. Liang Q., and Fulco A.J. Transcriptional regulation of the genes encoding cytochromes P450BM-1 and P450BM-3 in Bacillus megaterium by the binding of Bm 3R1 repressor to Barbie box elements and operator sites. J. Biol. Chem. 270 (1995) 18606
105. Liehr J.G., Ricci M.J., Jefcoate C.R., Hannigan E.V., Hokanson J.A., and Zhu B.T. 4-hydroxylation of estradiol by human uterine myometrium and myoma microsomes: Implications for the mechanism of uterine tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9220-9224
106. Loretz L.J., Li A.P., Flye M.W., and Wilson A.G.E. Optimization of cryopreservation procedures for rat and human hepatocytes. Xenobiotica 19 (1989) 489-498
107. Lown K., Kolars J., Turgeon K., Merion R., Wrighton S.A., and Watkins P.B. The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. Clin. Pharmacol. Ther. 51 (1992) 229-238
108. Lubet R.A., Nims R.W., Ward J.M., Rice J.M., and Diwan B.A. Induction of cytochrome P-450b and its relationship to liver tumor promotion. J. Am. Coll. Toxicol. 8 (1989) 259-268
109. Lucey M.R., Kolars J.C., Merion R.M., Campbell D.A., Aldrich M., and Watkins P.B. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335 (1990) 11-15
110. Mahgoub A., Idle J.R., Dring L.G., Lancaster R., and Smith R.L. Polymorphic hydroxylation of debrisoquine in man. Lancet 2 (1977) 584-586
111. Mansuy D., Battioni P., Chottard J.C., Riche C., and Chiaroni A. Nitrosoalkane complexes of iron-porphyrins: Analogy between the bonding properties of nitrosoalkanes and dioxygen. J. Am. Chem. Soc. 105 (1983) 455-463
112. Morel F., Beaune P.H., Ratanasavanh D., Flinois J.-P., Yang C.-S., Guengerich F.P., and Guillouzo A. Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur. J. Biochem. 191 (1990) 437-444
113. Muerhoff A.S., Griffin K.J., and Johnson E.F. Characterization of a rabbit gene encoding a clofibrate-inducible fatty acid ω-hydroxylase: CYP4A6. Arch. Biochem. Biophys. 296 (1992) 66-72
114. Nebert D.W. The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects. Crit. Rev. Toxicol. 20 (1989) 153-174
115. Nelson D.R., Kamataki T., Waxman D.J., Guengerich F.P., Estabrook R.W., Feyereisen R., Gonzalez F.J., Coon M.J., Gunsalus I.C., Gotoh O., Okuda K., and Nebert D.W. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 12 (1993) 1-51
116. Nocke-Finck L., Brewer H., and Reimers D. Wirkung van Rifampicin auf den Menstrationszylkus und die Östrogenausscheidung bei Einnahme oraler Kontrazeptive. Dtsch. Med. Wochenschr. 98 (1973) 1521-1523
117. Olsen J.H., Boice Jr. J.D., Jensen J.P.A., and Fraumeni Jr. J.P. Cancer among epileptic patients exposed to anticonvulsant drugs. J. Natl. Cancer Inst. 81 (1989) 803-808
118. Ortiz de Montellano P.R., and Correia M.A. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Annu. Rev. Pharmacol. Toxicol. 23 (1983) 481-503
119. Ortiz de Montellano P.R., and Reich N.O. Inhibition of cytochrome P-450 enzymes. In: Ortiz de Montellano P.R. (Ed). "Cytochrome P-450" (1986), Plenum, New York 273-314
120. Ortiz de Montellano P.R., Kunze K.L., Yost G.S., and Mico B.A. Self-catalyzed destruction of cytochrome P-450: Covalent binding of ethynyl sterols to prosthetic heme. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 746-749
121. Otton S.V., Inaba T., and Kalow W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 34 (1984) 73-80
122. Perrot N., Nalpas B., Yang C.S., and Beaune P.H. Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur. J. Clin. Invest. 19 (1989) 549-555
123. Quattrochi L.C., and Tukey R.H. Nuclear uptake of the Ah (dioxin) receptor in response to omeprazole: Transcriptional activation of the human CYP1A1 gene. Mol. Pharmacol. 43 (1993) 504-508
124. Raag R., and Poulos T.L. Crystal structures of cytochrome P-450CAM complexed with camphane, thiocamphor and adamatane: Factors controlling P-450 substrate hydroxylation. Biochemistry 30 (1991) 2674-2684
125. Ramsden R., Sommer K.M., and Omiecinski C.J. Phenobarbital induction and tissue-specific expression of the rat CYP2B2 gene in transgenic mice. J. Biol. Chem. 268 (1993) 21722-21726
126. Rando R.R. Mechanism-based enzyme inactivators. Pharmacol. Rev. 36 (1984) 111-142
127. Raney K.D., Shimada T., Kim D.-H., Groopman J.D., Harris T.M., and Guengerich F.P. Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: Significance of aflatoxin Q1 as a detoxication product of aflatoxin B1. Chem. Res. Toxicol. 5 (1992) 202-210
128. Rangarajan P.N., and Padmanaban G. Regulation of cytochrome P-450b/e gene expression by a heme- and phenobarbitone-modulated transcription factor. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 3963-3967
129. Rao M.S., and Reddy J.K. An overview of peroxisome proliferator-induced hepatocarcinogenesis. Environ. Health Perspect. 93 (1991) 205-209
130. Reimers D., and Jezek A. Rifampicin und andere Antituberkulotika bei gleichzeitiger oraler Kontrzeption. Przx. Pneumol. 25 (1971) 255-262
131. Remmer H. The acceleration of evipan oxidation and the demethylation of methylaminopyrine by barbiturates. Arch. Exp. Pathol. Pharmakol. 237 (1959) 296-307
132. Rettie A.E., Korzekwa K.R., Kunze K.L., Lawrence R.F., Eddy A.C., Aoyama T., Gelboin H.V., Gonzalez F.J., and Trager W.F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5 (1992) 54-59
133. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., and Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4 (1994) 39-42
134. Richardson H.L., Stier A.R., and Borsos-Nachrnebel E. Liver tumor inhibition and adrenal histologic responses in rats to which 3′-methyl-4-dimethylaminoazobenzene and 20-methylcholanthrene were simultaneously administered. Cancer Res. 12 (1952) 356-361
135. Roberts E.S., Hopkins N.E., Zaluzec E.J., Gage D.A., Alworth W.L., and Hollenberg P.F. Indentification of active-site peptides from 3H-labeled 2-ethynylnaphthaleneinactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry. Biochemistry 33 (1994) 3766-3771
136. Rodrigues A.D., Mulford D.J., Lee R.D., Surber B.W., Kukulka M.J., Ferrero J.L., Thomas S.B., Shet M.S., and Estabrook R.W. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P450 3A4 and NADPH-P450 reductase. Drug Metab. Dispos. 23 (1995) 765-775
137. Rost K.L., Brösicke H., Brockmöller J., Scheffler M., Helg H., and Roots I. Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin. Pharmacol. Ther. 52 (1992) 170-180
138. Rost K.L., Brösicke H., Heinemeyer G., and Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 20 (1994) 1204-1212
139. Sattler M., Guengerich F.P., Yun C.-H., Christians U., and Sewing K.-F. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. 20 (1992) 753-761
140. Schuetz E.G., Schuetz J.D., Thompson M.T., Fisher R.A., Madariage J.R., and Strom S.C. Phenotypic variability in induction of P-glycoprotein mRNA by aromatic hydrocarbons in primary human hepatocytes. Mol. Carcinog. 12 (1995) 61-65
141. Schwab G.E., Raucy J.L., and Johnson E.F. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol. Pharmacol. 33 (1988) 493-499
142. Sesardic D., Boobis A., Murray B., Murray S., Segura J., De La Torre R., and Davies D. Furafylline is a potent and selective inhibitor of cytochrome P450 1A2 in man. Br. J. Clin. Pharmacol. 29 (1990) 651-663
143. Shah R.R., Oates N.S., Idle J.R., Smith R.L., and Lockhart J.D.F. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br. Med. J. 284 (1982) 295-299
144. Silverman R.B. "Mechanism-based Enzyme Inactivation: Chemistry & Enzymology." (1988), CRC Press, Boca Raton, FL
145. Silverman R.B. Mechanism-based enzyme inactivators. "Methods in Enzymology," Vol. 249 (1995), Academic Press, San Diego, CA 240-283
146. Strobl G.R., von Kruedener S., Stöckigt J., Guengerich F.P., and Wolff T. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies. J. Med. Chem. 36 (1993) 1136-1145
147. Thull U., and Testa B. Screening of unsubstituted cyclic compounds as inhibitors of monoamine oxidases. Biochem. Pharmacol. 47 (1994) 2307-2310
148. K.E. Thummel D.D. Shen R.L. Carithers Jr. P. Hartwell T.D. Podoll W.F. Trager K.L. Kunze 1993). Prediction of in vivo midazolam clearance from hepatic CYP3A content and midazolam 1′-hydroxylation activity in liver transplant patients. Abstr., North Am. International Society for the Study of Xenobiotics Meet., 5th, Tucson, AZ, 1993, Vol. 4, p. 235
149. Tian G.C., Mook R.A., Moss M.L., and Frye S.V. Mechanism of time-dependent inhibition of 5 α-reductases by DL(1)-4-azasteroids: Toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 34 (1995) 13453-13459
150. Ueng Y.-F., Shimada T., Yamazaki H., and Guengerich F.P. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8 (1995) 218-225
151. Unge P., Svedberg L.E., Nordgren A., Blom H., Andersson T., and Lagerström P.O. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br. J. Clin. Pharmacol. 34 (1992) 509-512
152. Vincent S.H., Karanam B.V., Painter S.K., and Chiu S.H.L. In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch. Biochem. Biophys. 294 (1992) 454-460
153. Wang P., Mason P.S., and Guengerich F.P. Purification of human liver cytochrome P-450 and comparison to the enzyme isolated from rat liver. Arch. Biochem. Biophys. 199 (1980) 206-219
154. Wang R.W., Kari P.H., Lu A.Y.H., Thomas P.E., Guengerich F.P., and Vyas K.P. Biotransformation of lovastatin. IV. Identification of cytochrome P-450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch. Biochem. Biophys. 290 (1991) 355-361
155. Watkins P.B., Wrighton S.A., Maurel P., Schuetz E.G., Mendez-Picon G., Parker G.A., and Guzelian P.S. Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 6310-6314
156. Watkins P.B., Hamilton T.A., Annesley T.M., Ellis C.N., Kolars J.C., and Voorhees J.J. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin. Pharmacol. Ther. 48 (1990) 120-129
157. Waxman D.J., Attisano C., Guengerich F.P., and Lapenson D.P. Cytochrome P-450 steroid hormone metabolism catalyzed by human liver microsomes. Arch. Biochem. Biophys. 263 (1988) 424-436
158. Woosley R.L., Roden D.M., Duff H.J., Carey E.L., Wood A.J.J., and Wilkinson G.R. Co-inheritance of deficient oxidative metabolism of encainide and debrisoquine. Am. Soc. Clin. Invest. 29 (1981) 501
159. Woosley R.L., Chen Y., Freiman J.P., and Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. JAMA, J. Am. Med. Assoc. 269 (1993) 1532-1536
160. Wrighton S.A., and Stevens J.C. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22 (1992) 1-21
161. Yun C.-H., Hammons G.J., Jones G., Martin M.V., Hopkins N.E., Alworth W.L., and Guengerich F.P. Modification of cytochrome P450 1A2 enzymes by the mechanism-based inactivator 2-ethynylnaphthalene and the photoaffinity label 4-azidobiphenyl. Biochemistry 31 (1992) 10556-10563
162. Yun C.-H., Okerholm R.A., and Guengerich F.P. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: Role of cytochrome P450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. 21 (1993) 403-409
163. Zilly W., Breimer D.D., and Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol. 9 (1975) 219-227